ENCORAFENIB PLUS CETUXIMAB AS A NEW STANDARD OF CARE FOR PREVIOUSLY TREATED BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: UPDATED SURVIVAL RESULTS AND SUBGROUP ANALYSES FROM THE BEACON STUDY
BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators’ choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary analysis, encorafenib, binimetinib plus cetuximab (ENCO/BINI/CETUX; triplet) and encorafenib plus cetuximab (ENCO/CETUX; doublet) regimens improved overall survival […]
